Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | GALR3 | O60755 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 2/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.41 |
| ▸ | BCL2 | P10415 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TYR | P14679 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30777878 | 1.00 | ALOX15 (0.44) | ALOX15HPGDCES2GALR3CYP1A2 | |
| SCHEMBL15660887 | 0.83 | TYR (0.50) | ALOX15HPGDSMN1; SMN2HTTTYR | |
| SCHEMBL30396162 | 0.82 | ALDH1A1 (0.54) | ALOX15HPGDCES2GALR3CYP1A2 | |
| SCHEMBL82273 | 0.82 | ALDH1A1 (0.54) | ALOX15HPGDCES2GALR3CYP1A2 | |
| SCHEMBL9154085 | 0.81 | ALOX15 (0.48) | ALOX15HPGDCES2GALR3CYP1A2 | |
| SCHEMBL15658116 | 0.79 | MAPT (0.46) | ALOX15HPGDCES2GALR3CYP1A2 | |
| SCHEMBL8845029 | 0.79 | TYR (0.67) | ALOX15HPGDCASP1ALDH1A1SMN1; SMN2 | |
| SCHEMBL12806688 | 0.79 | MAOB (0.43) | POLBESR1ESR2 | |
| SCHEMBL11918441 | 0.79 | ALOX15 (0.46) | ALOX15HPGDCES2GALR3CYP1A2 | |
| SCHEMBL30380405 | 0.79 | ALOX15 (0.46) | ALOX15HPGDCES2GALR3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4712958-A2 | USE OF UROLITHIN DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Vandria SA (CH) | 2026-03-25 | — | — | EP | disclosed |
| US-12421349-B2 | Polyphenylene ether composition | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2025-09-23 | — | — | US | disclosed |
| EP-4561556-A2 | THERAPEUTIC USES OF UROLITHIN DERIVATIVES | Vandria SA (CH) | 2025-06-04 | — | — | EP | disclosed |
| EP-4561976-A2 | UROLITHIN AND FLUORENE DERIVATIVES FOR INHIBITING FERROPTOSIS | Vandria SA (CH) | 2025-06-04 | — | — | EP | disclosed |
| CN-119947717-A | Therapeutic use of urolithin derivatives | 范徳利亚股份公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119948002-A | Urolithin derivatives and therapeutic use | 范徳利亚股份公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20240424006-A1 | USE OF UROLITHIN DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | VANDRIA SA (CH) | 2024-12-26 | — | — | US | disclosed |
| WO-2024236367-A2 | USE OF UROLITHIN DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | VANDRIA SA (CH) | 2024-11-21 | — | — | WO | disclosed |
| CN-114514261-B | Polyphenylene ether composition | 旭化成株式会社 | 2024-09-10 | — | — | CN | disclosed |
| US-20240139149-A1 | THERAPEUTIC USES OF UROLITHIN DERIVATIVES | VANDRIA SA (CH) | 2024-05-02 | — | — | US | disclosed |
| US-20080176947-A1 | Heterocyclic-Substituted Alkanamides Useful as Renin Inhibitors | NOVARTIS AG (CH) | 2008-07-24 | — | — | US | disclosed |
| CN-101171230-A | Heterocyclic-substituted alkanamides useful as renin inhibitors | SPEEDEL EXPERIMENTA AG (CH) | 2008-04-30 | — | — | CN | disclosed |
| EP-1856032-A1 | HETEROCYCLIC-SUBSTITUTED ALKANAMIDES USEFUL AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006095020-A1 | HETEROCYCLIC-SUBSTITUTED ALKANAMIDES USEFUL AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-09-14 | — | — | WO | disclosed |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1380562-A1 | CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
| US-5350827-A | Photoresists in monolithographic process for photosensitive elements | OCG MICROELECTRONIC MATERIALS, INC. (US) | 1994-09-27 | — | — | US | disclosed |
| US-5338652-A | Coating substrate with mixture of novolak resins and o-quinonediazide for positive resist having improved resolution, then exposure, development | OCG MICROELECTRONIC MARTERIALS, INC. (US) | 1994-08-16 | — | — | US | disclosed |
| US-5306594-A | Positive working photoresist | OCG MICROELECTRONIC MATERIALS, INC. (US) | 1994-04-26 | — | — | US | disclosed |
| WO-1993009473-A1 | SELECTED STRUCTURALLY DEFINED NOVOLAK BINDER RESINS | OCG MICROELECTRONIC MATERIALS, INC. (US) | 1993-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240424006-A1 | USE OF UROLITHIN DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | UBQLN2, SOD1, UBQLN1 | ALOX15 844/4885HPGD 2759/4885CES2 1327/4885 |
| US-20080176947-A1 | Heterocyclic-Substituted Alkanamides Useful as Renin Inhibitors | REN, ACE, AGTR1 | ALOX15 2072/4885HPGD 504/4885CES2 294/4885 |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | GPR119, IRS1, SLC5A1 | ALOX15 1009/4885HPGD 2910/4885CES2 778/4885 |
| US-20240139149-A1 | THERAPEUTIC USES OF UROLITHIN DERIVATIVES | TNNT2, TNNI3, TNNC1 | ALOX15 1125/4885HPGD 856/4885CES2 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.